Near-infrared (NIR) fluorescent agent for in vivo imaging and other applications.
Please enter valid quantity
Please login to add favorites
NULL OR EMPTY CART
|Product Number||List Price||Your Price||Quantity|
You successfully added item(s) to your cart
Integrins are transmembrane cell surface receptors which mediate signal transduction, cell-to-cell interaction and cell-to extracellular matrix adhesion, key processes involved in angiogenesis, tumorigenesis and metastasis. Integrins have thus been hailed as clinically-relevant biomarkers of pathological conditions such as inflammation and tumor progression. The integrin avb3 is significantly upregulated in tumor cells and activated endothelial cells during neoangiogenesis.
IntegriSense™ 645 fluorescent imaging agent is used for in vivo detection of avb3 using a low molecular weight peptidomimetic antagonist coupled to a red fluorochrome. IntegriSense 645, an integrin-targeted molecular imaging agent allows the non-invasive imaging of disease status and progression. Pairing of an integrin antagonist treatment with IntegriSense 645 provides a mechanistic biomarker approach for assessing target coverage.
Disclaimer: For laboratory use only. This product is intended for animal research only and not for use in humans.
|Fluorescent Agent Type||Targeted|
|One Unit Contains||10 mouse dose|
|Optical Imaging Classification||Fluorescence Imaging|
|Product Brand Name||IntegriSense|
|Shipping Condition||Blue Ice|
|Therapeutic Area||Atherosclerosis, Oncology/Cancer, Angiogenesis|
|Unit Size||1 Vial (10 doses)|
|Wave Length||645 nm|
|Resource Type||File Name||File Format|
|Brochure||FMT Fluorescence Tomography in vivo Imaging Systems||PDF 1 MB|
|Brochure||In Vivo Imaging Agents Brochure||PDF 2 MB|
|Application Note||In Vivo Imaging of Atherosclerosis Disease Using FMT||PDF 1 MB|
|Technical Note||IntegriSense™ 645 (Data Sheet)||PDF 105 KB|
|Citations Library||View peer reviewed publications using PerkinElmer's In Vivo Imaging Reagents||Link|